A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
type: MedicalStudy
description: A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Immunogenicity of a 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Pichia Pastoris) in 9 to 45 Year Old Chinese Females
status: COMPLETED
study design: INTERVENTIONAL
phase: PHASE1
start date: 2019-03-09
end date: 2020-04-30
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT03900572
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Shanghai Zerun Biotechnology Co.,Ltd
study subject: HPV Infections
keywords: PHASE1
keywords: INTERVENTIONAL
keywords: COMPLETED
keywords: HPV Infections

AI Analytics
type: Organization